Cargando…
Human hypothalamus : neuroendocrine disorders /
| Clasificación: | Libro Electrónico |
|---|---|
| Otros Autores: | , , , , |
| Formato: | Electrónico eBook |
| Idioma: | Inglés |
| Publicado: |
[Place of publication not identified] :
Elsevier,
2021.
|
| Colección: | Handbook of clinical neurology ;
v. 181. |
| Temas: | |
| Acceso en línea: | Texto completo Texto completo |
MARC
| LEADER | 00000cam a2200000 a 4500 | ||
|---|---|---|---|
| 001 | SCIDIR_on1259510074 | ||
| 003 | OCoLC | ||
| 005 | 20231120010552.0 | ||
| 006 | m o d | ||
| 007 | cr |n||||||||| | ||
| 008 | 210709s2021 xx o 000 0 eng d | ||
| 040 | |a YDX |b eng |e pn |c YDX |d OPELS |d OCLCO |d UKAHL |d OCLCF |d UKMGB |d CASUM |d OCLCO |d QGK |d OCLCO |d OCLCQ |d SFB |d OCLCO |d K6U |d OCLCQ | ||
| 015 | |a GBC192099 |2 bnb | ||
| 016 | 7 | |a 020219586 |2 Uk | |
| 020 | |a 9780128206843 |q (electronic bk.) | ||
| 020 | |a 0128206845 |q (electronic bk.) | ||
| 020 | |a 9780128199749 |q (ePub ebook) | ||
| 020 | |a 0128199741 | ||
| 020 | |z 0128206837 | ||
| 020 | |z 9780128206836 | ||
| 035 | |a (OCoLC)1259510074 | ||
| 050 | 4 | |a QP383.7 | |
| 082 | 0 | 4 | |a 616.8 |2 23 |
| 245 | 0 | 0 | |a Human hypothalamus : |b neuroendocrine disorders / |c edited by Dick F. Swaab, Ruud M. Buijs, Paul J. Lucassen, Ahmad Salehi, Felix Kreier. |
| 246 | 3 | |a Neuroendocrine disorders | |
| 260 | |a [Place of publication not identified] : |b Elsevier, |c 2021. | ||
| 300 | |a 1 online resource | ||
| 336 | |a text |b txt |2 rdacontent | ||
| 337 | |a computer |b c |2 rdamedia | ||
| 338 | |a online resource |b cr |2 rdacarrier | ||
| 490 | 1 | |a Handbook of clinical neurology ; |v 181 | |
| 505 | 0 | |a Intro -- The Human Hypothalamus: Neuroendocrine Disorders -- Copyright -- Handbook of Clinical Neurology 3rd Series -- Foreword -- Preface -- The HCN volumes on the Human Hypothalamus -- The hypothalamus: Arbitrary borders -- References -- Contributors -- Contents -- Contents of related volumes -- Chapter 1: Introduction: The human hypothalamus and neuroendocrine disorders -- Section 15#: Structural Disorders of the Hypothalamo-pituitary Region -- Section 16: Tumors of the Hypothalamus -- Section 17: Neuroimmunological Disorders -- Section 18: Drinking Disorders -- Section 19: Eating Disorders -- Section 20: Reproduction and Sexual Behavior -- References -- Section 15: Structural disorders of the hypothalamo-pituitary region -- Chapter 2: Pituitary stalk interruption syndrome -- Introduction -- Epidemiology -- Magnetic Resonance Imaging findings -- Clinical Manifestations -- Hormonal Profile and Evolution of Hormone Deficiencies -- Treatment -- Pathogenesis of Pituitary Stalk Interruption Syndrome -- Genetics of Pituitary Stalk Interruption Syndrome -- Genes involved in pituitary organogenesis -- Genes involved in neural development -- Holoprosencephaly (HPE)-related genes -- Cilia-related genes -- PSIS associated with microdeletions or duplications -- Digenic and polygenic inheritance and the application of next generation sequencing -- Environmental Factors and PSIS -- Conclusions and Perspectives -- References -- Chapter 3: Empty sella syndrome: Multiple endocrine disorders -- Introduction -- Classification -- Epidemiology -- Pathogenesis of Empty Sella -- Presenting Clinical Manifestations -- Endocrine symptoms -- Neurological and ophthalmological symptoms -- Diagnosis -- Endocrinological assessment -- Ophthalmological assessment -- Radiological assessment -- Differential Diagnosis -- Treatment Strategies -- Hypopituitarism. | |
| 505 | 8 | |a Intracranial hypertension -- Follow-Up -- Prognosis -- Conclusion -- Acknowledgments -- Declaration in interest -- Funding -- References -- Chapter 4: Pituitary dysfunction after aneurysmal subarachnoidal hemorrhage -- Introduction -- Epidemiology -- Treatment and Management of aSAH -- Neuroendocrine Dysfunction in aSAH Patients -- Neuroendocrine Dysfunction in the Acute Phase after aSAH -- ACTH in the acute phase after aSAH -- FSH/LH in the acute phase after aSAH -- GH in the acute phase after aSAH -- TSH in the acute phase after aSAH -- Overall neuroendocrine dysfunction in the acute phase after aSAH -- Neuroendocrine Dysfunction in the Chronic Phase after aSAH -- ACTH in the chronic phase after aSAH -- FSH/LH in the chronic phase after aSAH -- GH in the chronic phase after aSAH -- TSH in the chronic phase after aSAH -- Overall neuroendocrine dysfunction in the chronic phase after aSAH -- Neuroendocrine Dysfunction in aSAH Patients: Changes from the Acute to the Chronic Phase -- Conclusions -- References -- Chapter 5: Septo-optic dysplasia -- Introduction -- Etiology and Pathogenesis -- Development of the Forebrain and Pituitary Gland -- Neuropathological Studies -- Epidemiology -- Clinical Presentation -- Visual disturbances -- Endocrinology disturbances -- Neurologic aspects -- Diagnostic Stage -- Ophthalmologic assessment -- Neuroradiology investigation -- Endocrinology workup -- Additional investigations -- Clinical and Surgical Management -- Prognosis and Outcome -- Conclusion -- Acknowledgments -- Disclosure -- References -- Section 16: Tumors of the hypothalamus -- Chapter 6: Hypothalamic hormone-producing tumors -- Introduction -- Tumor Classification, Clinical, and Morphological Features -- Therapeutic Approaches -- References -- Chapter 7: Craniopharyngiomas primarily affecting the hypothalamus -- Introduction1. | |
| 505 | 8 | |a Craniopharyngioma: A pituitary, suprasellar or hypothalamic tumor? -- Craniopharyngiomas primarily affecting the hypothalamus: Definition, anatomical relationships, and embryological origin -- Hypothalamus involvement by craniopharyngiomas: Historical insights -- Hypothalamus-referenced topographical classification of craniopharyngiomas -- Hypothalamic dysfunction caused by CPs: Infundibulo-tuberal syndrome versus hypothalamic syndrome -- Infundibulo-tuberal syndrome -- Hypothalamic syndrome -- Fr�ohlich's syndrome: Pathogenesis of sexual immaturity -- Hypothalamic obesity in craniopharyngioma patients -- Pathogenesis of hypothalamic obesity in Hy-CP patients: The role of astrogliosis -- Diurnal somnolence in CP patients -- Emotional, cognitive, and psychiatric disturbances: Clinical landmarks of Hy-CPs -- MRI assessment of CP-hypothalamus relationships: The usefulness of the mamillary body angle -- Surgical risk: The formidable problem of CP-hypothalamic adhesions -- Surgical strategies for CPs primarily affecting the hypothalamus -- Complications and sequelae derived from surgically caused hypothalamic injury -- Radiosurgery, proton beam therapy, and chemotherapy for the treatment of CPs involving the hypothalamus -- Genetic profile and targeted therapy for papillary CPs involving the hypothalamus -- Conclusions -- Acknowledgments -- Compliance with ethical standards -- Sources of funding -- Disclosure of potential conflict of interest -- Abbreviations -- References -- Section 17: Neuroimmunological disorders -- Chapter 8: The stress-axis in multiple sclerosis: Clinical, cellular, and molecular aspects -- Introduction -- The Stress-Axis in MS -- Determinants of Stress-Axis Responsiveness -- Neurodegeneration vs inflammation -- Sex and subtype-specific differences -- Differences in glucocorticoid receptor genotype. | |
| 505 | 8 | |a Pathological, Cellular, and Molecular Effects of Stress-Axis Responsiveness -- Clinical Correlates of HPA Axis Activity in MS -- Outlook -- References -- Chapter 9: Neuroendocrine manifestations of Langerhans cell histiocytosis -- Introduction -- Epidemiology -- Diagnostic Criteria -- Neuroendocrine Manifestations of LCH -- Anterior pituitary hormones deficiency -- Posterior pituitary hormones deficiency -- Hypothalamic involvement -- Others sites of involvement -- Management of LCH -- Chemotherapy -- Management of neuroendocrine manifestations in LCH -- Follow-up of LCH patients -- Conclusions -- References -- Chapter 10: Neuroendocrine manifestations of Erdheim-Chester disease -- Introduction -- Manifestations of Hypothalamus, Pituitary Stalk, and/or Pituitary Gland Lesions -- Manifestations of Posterior Pituitary Hormone Deficiencies (Arginine Vasopressin and/or Oxytocin Deficiencies) -- Manifestations of Anterior Pituitary Hormone Deficiencies -- ACTH Deficiency (Hypothalamic-Pituitary-Adrenal Axis) -- TSH Deficiency (Hypothalamic-Pituitary-Thyroid Axis) -- GH Deficiency -- Gonadotropin Deficiency (Hypothalamic-Pituitary-Gonadal Axis) -- Hyperprolactinemia -- PRL Deficiency -- Conclusions -- References -- Chapter 11: Hypothalamitis and pituitary atrophy -- Introduction -- Pathogenesis -- Clinical Presentation -- Diagnosis -- Neuroradiological features -- Differential Diagnosis -- Treatment -- Prognosis -- Conclusion -- References -- Chapter 12: Narcolepsy Type I as an autoimmune disorder -- Narcolepsy Type 1 -- Genetic Associations in Narcolepsy Type 1 -- Environmental Factors Linked to Disease Development -- Pathologic Findings Postmortem in Narcolepsy Type 1 -- Immune System Chances in Narcolepsy Type 1 Patients -- Circulating cytokines -- Autoantibodies -- T cells -- Animal Models of Narcolepsy Type 1. | |
| 505 | 8 | |a Is Narcolepsy Type 1 an Autoimmune Disease? -- References -- Chapter 13: Neuromyelitis optica, aquaporin-4 antibodies, and neuroendocrine disorders -- Neuromyelitis Optica Spectrum Disorders -- Introduction -- Epidemiological, clinical, and radiological features of AQP4-IgG NMOSD -- Circumventricular Organs and the Hypothalamus as Target of Aquaporin-4 Autoimmunity -- Aquaporin-4 expression and function in the hypothalamus -- The Spectrum of Neuroendocrine Disorders in Neuromyelitis Optica -- Syndrome of inappropriate antidiuresis -- Sleep disorders -- Other endocrinopathies caused by hypothalamic involvement in NMOSD -- Treatment of NMOSD -- References -- Chapter 14: Antibodies against the pituitary and hypothalamus in boxers -- Traumatic Brain Injury: Epidemiology, Causes, and Outcomes -- TBI and Neuroendocrine Abnormalities -- Autoimmunity and Hypothalamo-Pituitary Dysfunction -- Boxing and Autoimmunity -- Acknowledgment -- References -- Chapter 15: Autoimmune diabetes insipidus -- Introduction1 -- Autoantibody Studies -- Vasopressin cell antibodies in the diagnosis of autoimmune DI -- Autoantibodies to rabphilin-3A, a major target autoantigen in autoimmune DI -- Comparison of cytoplasmic AVPcAb and autoantibodies to rabphilin-3A -- Association of autoimmune DI with endocrine autoimmune diseases -- AVPcAb and antibodies to rabphilin-3A in normal individuals without diabetes insipidus -- Imaging: MRI of the brain and the pituitary gland, and FDG-PET -- Relevance of AVPcAb and pituitary stalk thickening for the diagnosis of autoimmune DI -- Immunohistochemical studies -- The clinical picture of autoimmune DI -- Association of lymphocytic infundibuloneurohypophysitis with lymphocytic anterior hypophysitis -- Natural course of autoimmune DI/LINH -- Treatment of autoimmune CDI/LINH -- Autoimmune DI following therapy with immune checkpoint inhibitors. | |
| 650 | 0 | |a Hypothalamus. | |
| 650 | 0 | 2 | |a Humans |0 (DNLM)D006801 |
| 650 | 1 | 2 | |a Hypothalamus |0 (DNLM)D007031 |
| 650 | 2 | 2 | |a Hypothalamus |x abnormalities |0 (DNLM)D007031Q000002 |
| 650 | 6 | |a Hypothalamus. |0 (CaQQLa)201-0023938 | |
| 650 | 7 | |a Hypothalamus. |2 fast |0 (OCoLC)fst00966079 | |
| 655 | 4 | |a Internet Resources. | |
| 655 | 4 | |a Index not Present. | |
| 700 | 1 | |a Swaab, D. F. |q (Dick Frans) | |
| 700 | 1 | |a Buijs, Ruud M. | |
| 700 | 1 | |a Lucassen, Paul J. | |
| 700 | 1 | |a Salehi, Ahmad. | |
| 700 | 1 | |a Kreier, Felix. | |
| 776 | 0 | 8 | |i Ebook version : |z 9780128199749 |
| 776 | 0 | 8 | |i Print version: |t Human hypothalamus. |d [Place of publication not identified] : Elsevier, 2021 |z 0128206837 |z 9780128206836 |w (OCoLC)1233167260 |
| 830 | 0 | |a Handbook of clinical neurology ; |v v. 181. | |
| 856 | 4 | 0 | |u https://sciencedirect.uam.elogim.com/science/handbooks/00729752/181 |z Texto completo |
| 856 | 4 | 0 | |u https://sciencedirect.uam.elogim.com/handbook/handbook-of-clinical-neurology/vol/181/suppl/C |z Texto completo |